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analyses showed no relationship between PK, pCR, and 
grade ≥3 AEs for either regimen.
Conclusion A fixed 600 mg SC dose of trastuzumab pro-
vides the desired exposure, with steady-state trough con-
centrations (35–123 μg/mL for the 5th–95th percentiles) 
above the historical target concentration of 20 μg/mL for 
efficacy. Fixed dosing is further supported by lack of an 
exposure–response relationship between PK, pCR, and 
grade ≥3 AEs. No dose adjustment per patient factors is 
required within the ranges studied.
Keywords Early breast cancer · Fixed dose · HER2 · 
NONMEM · Population pharmacokinetics modeling · 
Trastuzumab
Introduction
Trastuzumab is a humanized immunoglobulin G1 (IgG1) 
monoclonal antibody against the extracellular domain of 
human epidermal growth factor receptor 2 (HER2) [1, 2]. 
Trastuzumab is currently licensed in the USA/EU for treat-
ment of patients with HER2-positive early breast cancer 
(EBC) (in combination with neoadjuvant and/or adju-
vant chemotherapy), HER2-positive metastatic breast 
cancer (MBC) (as monotherapy or in combination with 
pertuzumab plus docetaxel, or with lapatinib, paclitaxel, 
docetaxel, or an aromatase inhibitor), and HER2-positive 
metastatic gastric cancer (in combination with capecitabine 
or 5-fluorouracil and cisplatin) [3, 4]. The approved intra-
venous (IV) regimens for breast cancer include an 8 mg/kg 
loading dose followed by 6 mg/kg maintenance doses 
administered every 3 weeks (q3w) or a 4 mg/kg loading 
dose followed by a 2 mg/kg weekly (qw) maintenance dose 
[3, 4]. IV administration can be time-consuming and may 
Abstract 
Purpose To characterize the population pharmacoki-
netics (PKs) of subcutaneous (SC) and intravenous (IV) 
trastuzumab in early breast cancer (EBC), assess the impact 
of covariates on trastuzumab PK, and evaluate fixed (non-
weight-based) dosing for the SC regimen administrated via 
handheld syringe.
Methods Serum trastuzumab concentrations from 
595 patients with HER2-positive EBC in the HannaH study 
(fixed 600 mg SC trastuzumab or weight-based IV trastuzumab) 
were analyzed using nonlinear mixed-effects modeling. 
Multiple logistic regression was used to assess the expo-
sure–response relationships between PK, efficacy [patho-
logic complete response (pCR)], and safety [grade ≥3 
adverse events (AEs)].
Results Trastuzumab PK was described by a two-com-
partment model with parallel linear and nonlinear elimi-
nation and first-order SC absorption, with a bioavailabil-
ity of 77 %. Estimated total clearance (CL) values were 
0.18–0.22 L/day for steady-state trough/peak concentra-
tions of 75–148 µg/mL; the estimate for central volume of 
distribution was 2.9 L. Body weight and alanine transam-
inase, while showing significant effects on PK, only 
explained 8 % of the variability in CL. Exposure–response 
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result in patient discomfort, whereas a subcutaneous (SC) 
fixed-dose administration can be delivered in <5 min without 
IV access, thereby increasing the overall convenience of 
trastuzumab administration [5]. A 600 mg fixed SC dose of 
trastuzumab, administered by manual injection/handheld 
syringe q3w, has been approved in the EU and in a number 
of non-EU states (Argentina, Chile, Costa Rica, Macedo-
nia, Norway, Panama, Peru, South Korea, and Uruguay) [4, 
6]. This administration contains recombinant human hya-
luronidase (rHuPH20), which temporarily degrades hyalu-
ronan at the injection site to facilitate injection of the 5 mL 
dosing volume [7].
The pharmacokinetics (PKs) of IV trastuzumab were 
previously characterized in patients with HER2-positive 
MBC using a population PK (PopPK) model [8]. Here, a 
two-compartment model with linear clearance (CL) was 
sufficient to describe the PK of trastuzumab [8, 9]. Body 
weight was an important covariate, with increased CL and 
central volume of distribution (Vc) in heavier patients [8, 
9]. To identify the SC dose for the HannaH study, a PopPK 
model for SC trastuzumab was developed based on a phase 
I study (NCT00800436), in which abundant PK data were 
obtained from 24 healthy volunteers and 42 patients with 
HER2-positive EBC receiving single, weight-adjusted 
doses of SC and/or IV trastuzumab [5]. A PopPK model 
consisting of a two-compartment model with parallel lin-
ear and nonlinear (Michaelis–Menten) elimination from the 
central compartment was then used to verify that a fixed-
dose SC regimen of 600 mg would achieve a trough con-
centration (Cmin) noninferior to the IV regimen [10]. The 
nonlinear CL has been reported for other monoclonal anti-
bodies and is thought to reflect target-mediated drug dispo-
sition [11]. In addition, the concentrations for the 600 mg 
SC dose are expected to consistently exceed the historical 
efficacy Cmin target of 20 μg/mL identified in preclinical 
studies [12].
HannaH (NCT00950300) was a phase III, randomized, 
international, open-label trial in the neoadjuvant–adjuvant 
setting, conducted to establish noninferiority of fixed-
dose SC trastuzumab with the approved weight-based IV 
q3w regimen [13]. Patients with HER2-positive, oper-
able, locally advanced, or inflammatory breast cancer were 
randomized 1:1 to receive eight cycles of neoadjuvant 
chemotherapy and concurrent trastuzumab q3w, admin-
istered either IV (8 mg/kg loading dose, 6 mg/kg mainte-
nance dose) or SC (600 mg fixed dose). Following surgery, 
patients continued trastuzumab q3w to complete 1 year of 
adjuvant therapy. Cmin and pathologic complete response 
(pCR) were coprimary endpoints. The geometric mean 
ratio of presurgery (precycle 8) Cmin in the SC and IV arms 
was 1.33, with two-sided 90 % confidence interval (CI) of 
1.24–1.44, the lower limit of which was higher than the 
prespecified noninferiority margin of 0.80. The pCR rates 
were 40.7 and 45.4 % in the IV and SC arms, respectively, 
a difference of 4.7 % (95 % CI −4.0, 13.4); the lower limit 
of the two-sided 95 % CI was higher than the prespecified 
noninferiority margin of −12.5 %. Thus, noninferiority 
of SC versus IV trastuzumab was demonstrated for both 
endpoints.
We present results from the PopPK analysis of HannaH. 
The key objectives of this analysis were (1) to character-
ize the PopPK of trastuzumab in the SC “manual syringe” 
injection and IV administrations, (2) to assess the effect of 
patient characteristics on trastuzumab PK, (3) to explore 
the exposure–response relationship between PK, pCR, and 
grade ≥3 adverse events (AEs) for the SC regimen, and (4) 




HannaH enrolled 596 patients with HER2-positive EBC, 
595 of whom received at least one dose of trastuzumab. 
Patients were randomized to receive either SC (fixed 
600 mg SC dose; n = 297) or IV (8 mg/kg IV loading 
dose, 6 mg/kg IV maintenance dose; n = 298) trastuzumab 
(Herceptin®, F. Hoffmann-La Roche, Basel, Switzer-
land) q3w, for a total of 18 cycles over 1 year of therapy 
(Online Resource 1). Briefly, all patients received concomi-
tant chemotherapy during the first eight presurgery cycles 
(neoadjuvant phase) and trastuzumab monotherapy for the 
remaining ten post-surgery cycles (adjuvant phase). SC 
trastuzumab was injected with a manual handheld syringe 
over 5 min; IV trastuzumab was administered as an initial 
90-min infusion with subsequent 30-min infusions. Safety 
analyses were performed after approximately 20 months 
of follow-up [14]. The study was conducted in accordance 
with the Declaration of Helsinki, and the protocol and all 
amendments thereof were approved by an independent 
ethics committee. Participants provided written informed 
consent.
PK data included in the analysis
Blood samples for serum trastuzumab concentration were 
collected at peak (post-infusion) and trough (preinfusion) 
time points in cycles 1–13 for the IV group and at trough 
time points for the SC group. Additional PK samples were 
collected at cycle 7 (during neoadjuvant treatment) and 
cycle 12 (during adjuvant treatment) for both groups to 
determine the concentration–time profile for noncompart-
mental PK analysis and comparison of PK during neoad-
juvant and adjuvant treatment phases (Online Resource 2). 
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All PK data from cycles 1 to 13 were used in this analy-
sis. Results from the phase I study (NCT00800436) were 
not included in this analysis because that study included 
as patients with EBC and healthy male volunteers were 
present, and not all data from the relevant covariates were 
collected.
Efficacy data included in the analysis
pCR was defined as “absence of invasive neoplastic cells in 
the breast.” Since the noninferiority hypothesis was to be 
tested, the per-protocol population was the primary analy-
sis population.
Safety data included in the analysis
AEs were graded according to National Cancer Institute 
Common Terminology Criteria for Adverse Events (NCI-
CTCAE V3.0) [15].
Serum trastuzumab concentration assays
Serum trastuzumab concentrations were determined using a 
validated receptor binding, enzyme-linked immunosorbent 
assay (ELISA). The lower limit of quantification (LLOQ) 
of the assay is 0.156 μg/mL [16].
PK data handling
Patients were defined as evaluable for PK analysis if they 
had at least one adequately documented dose of trastu-
zumab and a corresponding PK sample. Records were 
excluded if the time of drug administration or sample col-
lection was missing.
Observations below the LLOQ were omitted. A more 
sophisticated analysis method, e.g., a censored-data likeli-
hood method, was not deemed necessary for HannaH, since 
it was a multiple dosing study where most PK samples 
were at steady state with concentrations >20 µg/mL (sub-
stantially higher than the LLOQ of 0.156 μg/mL).
Outliers were identified using an initial two-com-
partment model with linear elimination from the central 
compartment, first-order absorption of the SC regimen, 
and a proportional plus additive residual error model. 
Data with weighted residuals (WRES) >3 or conditional 
weighted residuals (CWRES) >3 of the initial model 
were considered to be potential outliers and omitted 
from the PopPK analysis. A sensitivity analysis, where 
the final model was reestimated using all data includ-
ing outliers, was performed and the parameter estimates 
compared. Observations below the minimum quanti-
fiable concentration limit were also omitted from the 
PopPK analysis.
PopPK analysis
The PopPK methods were based on the FDA’s Guidance 
for Industry: Population Pharmacokinetics [17]. 
Trastuzumab PK data were analyzed by nonlinear mixed-
effects modeling with NONMEM version 7.1.2 (ICON 
Development Solutions, Ellicott City, MD, USA) using the 
first-order conditional estimation method with interaction 
(FOCEI). Perl-speaks-NONMEM (PsN, version 3.2, http://
psn.sourceforge.net/) was used to aid the model devel-
opment; S-PLUS (TIBCO Software Inc., Palo Alto, CA, 
USA) and R statistical software [18] were used for data 
assembly, exploratory data analysis, model diagnosis, and 
model simulations.
Models were evaluated based on the likelihood objective 
function value (OFV) provided by NONMEM, graphical 
evaluation, and precision of the parameter estimates (rela-
tive standard error [RSE]).
A two-step approach was used for covariate identifi-
cation [19]. In the first step, a univariate screening of the 
covariates was conducted. Only the covariates that showed 
a significant (p < 0.01) effect on the estimated PK param-
eters and could be meaningfully explained from both a 
clinical and scientific perspective, were carried through 
to the second step. The second step was a stepwise, back-
ward elimination process, starting with the full model and 
removing each covariate one at a time. The least significant 
covariate was removed, and the process was repeated. The 
level of significance to retain a covariate was p < 0.001. In 
the final model, all retained covariates are considered to be 
statistically significant.
The effects of continuous covariates were modeled as 
follows:
The effects of categorical covariates were modeled as 
follows:
where θ is a PK model parameter, Cov is a continuous 
covariate, X is an indicator variable for a categorical covari-
ate, i is the index for the subject, pop is an index denoting 
the typical value in the population, and kcov is a coefficient 
describing the strength of the covariate effect on the PK 
parameter.
Patient factors evaluated as covariates were selected 
based on potential clinical relevance and previous experi-
ence with trastuzumab and other monoclonal antibodies. 
For CL, these were: patient demographics (age, baseline 
body weight, race), baseline laboratory measurements 
[alkaline phosphatase (ALK), serum albumin (ALBU), 





θi = θpop · e
kcovXi
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total bilirubin (TBIL), aspartate transaminase (AST), ala-
nine transaminase (ALT), creatinine clearance (CrCL)], 
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status, treatment setting (neoadjuvant or adjuvant), 
HER2 overexpression level, and immunogenicity variables 
[anti-trastuzumab antibodies (ATAs) and anti-hyaluroni-
dase antibodies (AHAs)]. For Vc, these were: patient demo-
graphics, ECOG performance status, and HER2 overex-
pression level. For peripheral volume of distribution (Vp), 
these were: baseline body weight, race, and HER2 over-
expression level. Where covariate data were missing for 
≤10 % of the patients, continuous covariates were imputed 
as the population median and categorical covariates were 
categorized as the reference category.
The final PK model was evaluated using internal vali-
dation procedures: nonparametric bootstrap resampling 
techniques (n = 1000 trial replicates) stratified by treat-
ment arm and visual and numerical predictive checks [20] 
(n = 1000) stratified by treatment arm.
The extent of shrinkage derived from the final model 
was assessed for each between-subject variability term (η), 
as well as for residual error (ε). High η shrinkage indicates 
a lack of information for a reliable estimate of the indi-
vidual empirical Bayes PK parameter estimates (EBEs); 
interpretation of EBEs should be approached with caution 
whenever substantial η- or ε-shrinkage exists (e.g., >30 %) 
[21].
Evaluation of body weight impact on PK parameters
The impact of baseline body weight on the predicted 
steady-state trough concentration (Cmin,ss) and area under 
the curve (AUCss) was evaluated with simulations from 
resampling of the EBEs. The simulation takes into account 
potential correlation of between-subject variability with 
covariates. In addition, stochastic simulations of 100 trials 
were performed using the observed set of covariate values 
of all patients from HannaH, to account for potential cor-
relation among covariates, random variability between sub-
jects, and random residual variability.
PK exposure–response analysis
The relationship between pCR and Cmin,ss was assessed 
using a multiple logistic regression (MLR) analysis for 
pCR with the covariates Cmin,ss, body weight, and treat-
ment arm, and all interactions with treatment arm. Body 
weight was included in the analysis as the use of a fixed 
dose might result in higher exposure in lighter patients than 
in heavier patients; weight-based IV dosing was expected 
to result in higher exposure in heavier patients.
The relationship between grade ≥3 AEs and AUCss was 
assessed using MLR for incidence of grade ≥3 AEs and 
the covariates AUCss, body weight, treatment arm, and all 
interactions with the treatment arm.
The estimated odds ratios and corresponding 95 % CIs 
from the fitted models were graphically represented for 
patients with specified body weights and model-predicted 
PK parameters. These values were determined by select-
ing the first quartile (25th percentile), second quartile 
(median), and third quartile (75th percentile) of the popula-
tion distribution.
Results
Patient population and PK samples
HannaH enrolled 596 patients, 595 of whom received at 
least one dose of trastuzumab (297 patients in the SC arm 
and 298 patients in the IV arm). There were 6403 PK sam-
ples collected in the SC arm [including 95 (1.5 %) outliers 
from 72 patients] and 9790 samples collected in the IV arm 
[including 337 (3.4 %) outliers from 138 patients]. Typi-
cally, only one or two samples per patient (out of 24 and 36 
planned samples per patient in the SC and IV arms, respec-
tively) were excluded during the 13 treatment cycles. All 
data from three patients were excluded because >10 sam-
ples from each of these patients were outliers. All identified 
outliers were visually inspected, and it was confirmed that 
there was no bias against low versus high trough concen-
trations. The identified outliers were mainly trough con-
centrations that were greater than the peak concentration 
and/or vice versa. The dataset for PK model development 
contained 592 patients and 15,761 trastuzumab serum PK 
samples. A final sensitivity analysis, where all data, includ-
ing outliers, were included, was performed and resulted 
in similar parameter estimates. Patient demographics and 
laboratory and disease covariates are summarized in Online 
Resource 3.
Trastuzumab PK
The final PK model (Online Resource 4) was a two-com-
partment model with parallel linear and nonlinear (Michae-
lis–Menten) elimination from the central compartment. SC 
absorption was modeled as a first-order process. PK param-
eter estimates for trastuzumab (Table 1) were well defined 
(RSE < 39 %), as assessed by a stratified nonparametric 
bootstrap procedure. Of the 1000 datasets generated for 
bootstrapping, 941 (94.1 %) runs minimized successfully. 
Between-subject variability was modeled using a log-normal 
variance model, and the residual error variability was 
described by a combined proportional plus additive resid-
ual error model.
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Goodness-of-fit plots showed good agreement between 
predicted and observed concentrations, with no bias in 
residuals over time and across predicted concentration val-
ues (Online Resource 5). There was an acceptable level of 
shrinkage for all trastuzumab PK parameters: 11.5 % for 
CL, 22.3 % for Vc, and 19.1 % for Vp.
Visual predictive checks stratified by administration (SC 
or IV) evaluated the ability of the model to reproduce the 
distribution of the observed PK data. The visual predic-
tive check (Fig. 1) showed that the model mimics the cen-
tral tendency and the spread of the PK in both the SC and 
IV populations. The plots were also stratified by quartiles 
of baseline body weight, and the model matched the PK 
of patients with low or high body weight. In the numeri-
cal predictive check calculation, the 5th, 25th, 50th, 75th, 
and 95th percentiles of the model predictions corresponded 
to the 4, 21, 50, 77, and 95 % quartiles of the observed 
concentrations, respectively. Therefore, both visual and 
numerical predictive checks suggested that the model 
adequately describes the distribution of trastuzumab PK 
concentrations.
At clinically relevant steady-state concentrations (Online 
Resource 6), total CL was estimated to decrease from 
trough to peak serum concentrations: 0.22–0.18 L/day CL 
for trough/peak concentrations of 75–148 µg/mL (SC regi-
men); 0.24–0.17 L/day CL for trough/peak concentrations 
of 57–170 µg/mL (IV regimen). Model simulations 
determined that 90 % of steady-state PK (Cmin,ss) was 
achieved by approximately cycle 6 (126 days) and cycle 5 
(105 days) for the SC and IV regimens, respectively. Cmin 
reached steady state later than Cmax and AUC because the 
impact of nonlinear clearance is more significant at low 
concentrations.
Impact of patient characteristics and pathophysiology 
on trastuzumab PK
CL patient characteristics included: patient demographics 
(age, baseline body weight, and race), baseline laboratory 
measurements (ALK, ALBU, TBIL, AST, ALT, and CrCL), 
ECOG performance status, treatment setting (neoadjuvant 
or adjuvant), HER2 overexpression level, and immuno-
genicity variables (ATAs and AHAs). For Vc, these were: 
patient demographics, ECOG performance status, and 
HER2 overexpression level. For Vp, these were: baseline 
body weight, race, and HER2 overexpression level.
The effect of patient demographics, baseline labora-
tory measurements, renal function (CrCL), immunogenic-
ity, and disease factors on PK parameters was assessed. 
The covariates identified in the univariate screening step 
to have a significant (p < 0.01) impact on PK included: 
body weight, ALT, ALBU, CrCL, TBIL, and ALK on CL; 
Table 1  Final population pharmacokinetic parameters for trastuzumab
ALT, alanine transaminase; CV, coefficient of variation; Km, concentration at which the nonlinear clearance rate is half of Vmax; RSE, relative 
standard error; SC, subcutaneous
CLi = 0.111 · (WTi/68)1.04 · (ALTi/19)0.144




= 3.06 · (WTi/68)
0.500
Parameter Population estimate (% RSE) Between-subject variability (CV %) Bootstrap estimate, median 
(2.5, 97.5 percentile)
Bioavailability of SC regimen (−) 0.771 (1.45) 13.0 0.773 (0.747, 0.797)
First-order SC absorption rate  
[Ka (day−1)]
0.404 (2.92) – 0.403 (0.381, 0.429)
Linear CL (L/day) 0.111 (10.3) 30.0 0.115 (0.094, 0.153)
Vmax (mg/day) 11.9 (19.9) – 11.0 (5.2, 16.3)
Km (mg/L) 33.9 (38.6) – 28.5 (5.69, 67.2)
Vc (L) 2.91 (1.24) 19.1 2.92 (2.85, 3.00)
Q (L/day) 0.445 (10.5) – 0.444 (0.314, 0.539)
Vp (L) 3.06 (3.23) 50.4 3.08 (2.88, 3.31)
Influence of body weight on linear CL 1.04 (11.3) – 0.998 (0.695, 1.26)
Influence of body weight on Vc 0.443 (11.3) – 0.445 (0.336, 0.535)
Influence of body weight on Vp 0.500 (22.2) – 0.481 (0.200, 0.735)
Influence of ALT on linear CL 0.144 (20.8) – 0.136 (0.085, 0.205)
Proportional variability (%) 23.9 (3.62) – 23.9 (23.0, 24.7)
Additive variability (µg/mL) 4.48 (21.7) – 4.43 (3.33, 5.27)
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body weight and race on Vc; body weight on Vp. Follow-
ing the backward elimination step, the only two covariates 
remaining with a significant (p < 0.001) impact on PK were 
body weight (increased body weight resulted in increased 
CL and Vc) and ALT (increased ALT resulted in increased 
CL); parameter–covariate relationships included in the final 
model are given in Table 1.
After inclusion of body weight and ALT in the final 
model, between-subject variability decreased from 31.3 
to 30.0 % for linear CL, from 20.1 to 19.1 % for Vc, and 
from 59.4 to 50.4 % for Vp, compared with the base model 
without covariates. Therefore, 8 % of the total variability 
in linear CL was explained by body weight and ALT, 10 % 
of the variability in Vc was explained by body weight, and 
28 % of the variability in Vp was explained by body weight. 
Inclusion of the covariates did not result in any change in 
the residual error magnitude.
A sensitivity analysis was performed to examine the 
influence of covariates on trastuzumab exposure (Cmin,ss 
and AUCss) with the SC regimen (Online Resource 7). Pre-
dicted Cmin,ss varied from 35 to 123 μg/mL (5th–95th per-
centiles) across the overall patient population, representing 
a −54 to +63 % change from the reference patient [Cmin,ss 
75.4 μg/mL (with body weight 68 kg and ALT 19 IU/L)], 
while variability in body weight resulted in a −31 to 
+39 % change. The effect of ALT on Cmin,ss was minimal, 
within the range of −14 to +13 %. The effect of body 
weight and ALT showed a similar trend for AUCss.
No other tested covariates, including demographic vari-
ables (age and race), other laboratory variables reflecting 
hepatic function (ALBU, AST, and TBIL) or renal function 
(CrCL), ALK, ECOG performance status, HER2 expres-
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Fig. 1  Simulated and observed concentrations with the SC (top) and 
IV (bottom) regimens. IV, intravenous; SC, subcutaneous. Circles 
are observed trastuzumab serum concentrations; solid lines represent 
the median observed values; dashed lines represent 5 and 95 % pre-
diction intervals of the observed values; shaded areas represent the 
median predicted values or the spread (5 and 95 %) of the predicted 
concentrations; the width of the shaded areas indicate 95 % CIs; left 
panel shows the entire time course while the right panel shows cycle 
7 only
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and AHAs) or disease status (neoadjuvant vs. adjuvant) had 
statistically significant effects on trastuzumab PK.
Impact of body weight on exposure with SC and IV 
regimens
Since the IV regimen was weight-adjusted, patients with 
greater baseline body weight received a greater absolute 
dose. Weight-adjusted dosing overcompensates for the 
effect of body weight on trastuzumab PK and results in 
greater exposure in heavier patients. The effect is reversed 
in patients receiving the SC regimen (lesser exposure for 
heavier patients) because patients received a fixed dose. 
In spite of the impact of body weight on exposure, there 
was a large overlap in the distribution of Cmin,ss and AUCss 
across the body weight range, for both regimens. Trastu-
zumab concentrations in heavier SC patients were similar 
or higher when compared with all body weight ranges or 
groups of IV patients (Fig. 2; Online Resource 8). Fur-
thermore, most patients (98 % for SC and 99.5 % for IV) 
achieved or exceeded the historical target Cmin,ss of 20 μg/
mL (based on preclinical xenograft efficacy models) [12].
Impact of regimen on PK
Typical predicted trastuzumab concentration–time profiles 
were compared for three regimens: IV (8 mg/kg loading 
dose followed by 6 mg/kg q3w, 4 mg/kg loading dose fol-
lowed by 2 mg/kg qw) and SC (fixed 600 mg q3w) (Fig. 3). 
The simulation comprised reference patients with body 
weight 68 kg and ALT 19 IU/L. At steady state (cycle 7, 
right panel), the SC regimen produced greater trastuzumab 
concentrations than the IV regimens during the majority 
of treatment cycles, while the q3w IV regimen (8/6 mg/
kg) had a higher peak concentration. The peak concentra-
tion (Cmax,ss) of the SC regimen at steady state was reached 
around 4 days post-dose. Predicted Cmin,ss was 57, 75, and 
75 µg/mL for the IV 8/6 mg/kg q3w, IV 4/2 mg/kg qw, and 
SC 600 mg q3w dosing regimens, respectively (Online 
Resource 9). The higher Cmin,ss for SC dosing is attributed 
to the 600 mg fixed dose selected and, for the qw regimen, 
to a lesser effect of the nonlinear clearance component than 
that seen in the q3w schedule. The predicted Cmax,ss was 
182, 116, and 149 µg/mL for the three dosing regimens, 
with the lower Cmax of the SC 600 mg q3w regimen and 
the IV 4/2 mg/kg qw regimen reflecting the longer absorp-
tion period of the SC regimen and the lower dose of the 
IV 4/2 mg/kg qw regimen, respectively. The predicted 
AUCss over a 3-week period was similar between regimens, 
with values of 1994, 1951, and 2337 µg day/mL for the IV 
8/6 mg/kg q3w, IV 4/2 mg/kg qw, and SC 600 mg q3w dos-
ing regimens, respectively.
PK exposure–response relationships
The per-protocol population included in the exposure–
response analyses comprised 260 and 263 patients in the 































Fig. 2  Impact of body weight on Cmin,ss for the fixed-dose SC regi-
men (left) and the weight-based IV regimen (right). Cmin,ss, steady-
state trough concentration; IV, intravenous; q3w, every 3 weeks; SC, 
subcutaneous. Cmin,ss following administration of a fixed 600 mg dose 
SC q3w regimen (left) and a weight-based 8 mg/kg loading dose, 
6 mg/kg maintenance dose IV q3w regimen (right). Circles are the 
individual model-predicted Cmin,ss values for patients in the HannaH 
study. The solid line shows the impact of body weight on Cmin,ss in 
patients with typical pharmacokinetics. The dashed area represents 
the spread (5 and 95 %) based on stochastic simulations (n = 300 for 
each body weight value), including between-subject variability. The 
dotted horizontal line is the 20 μg/mL target Cmin,ss based on preclini-
cal xenograft efficacy models
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the IV and SC arms irrespective of body weight or quar-
tiles of predicted exposure, with the exception of the low-
est body weight quartile (<58 kg) and the second highest 
Cmin,ss quartile (≥61.5 μg/mL, <78.2 μg/mL), where pCR 
rates [54 % (n = 56) and 53 % (n = 73), respectively] were 
higher in the SC arm (Table 2; Online Resource 10); while 
this analysis is limited by the small sample sizes of the sub-
groups, pCR rates were similar across Cmin,ss and AUCss 
quartiles, for both arms.
MLR showed that none of the parameters investigated 
(Cmin,ss, body weight, treatment arm, and interaction terms 
with treatment arm) impacted the primary efficacy end-
point, pCR (p > 0.1 for all, Online Resource 11). The 
estimated odds ratios and corresponding 95 % CIs from 
the fitted model are graphically represented in Fig. 4a for 
patients with specified body weights (59, 68, and 80 kg) 
and model-predicted Cmin,ss values (46, 62, and 78 μg/mL). 
The estimated odds ratios for pCR were similar in each 
subgroup, with overlapping CIs. Hence, no statistically rel-
evant impact of predicted Cmin,ss or body weight on pCR 
was observed.
The safety population in the exposure–response analy-
ses comprised 297 and 298 patients in the SC and IV 
arms, respectively. No clinically meaningful pattern was 
observed in grade ≥3 AE rates within the quartile groups 
of model-predicted Cmin,ss, AUCss, or body weight quartile 
groups in either the SC or IV treatment groups (Table 2; 
Online Resource 12). Rates were generally comparable 
between the two arms, and there was no pattern suggestive 
of an increase in grade ≥3 AEs with increasing exposure or 
decreasing body weight [14].
MLRs for grade ≥3 AEs demonstrated that none of the 
covariates had a significant effect on the probability of 
grade ≥3 AEs (p values of parameter estimates were >0.05, 
Online Resource 13). The estimated odds ratios for grade 
≥3 AEs were similar in each subgroup, with overlapping 
CIs (Fig. 4b). Hence, no statistically relevant impact of pre-
dicted AUCss or body weight on occurrence of grade ≥3 AE 
was observed.
Discussion
Trastuzumab PK was evaluated in 595 female patients with 
HER2-positive EBC receiving trastuzumab in the neo-
adjuvant and adjuvant settings in the phase III HannaH 
study using a population modeling approach. In addition, 
the relationship between trastuzumab exposure, efficacy 
(pCR), and safety (grade ≥3 AEs) during neoadjuvant treat-
ment was evaluated. Patients were randomized to receive 
either a fixed 600 mg SC regimen (q3w) or the IV regimen 
(8 mg/kg loading dose followed by 6 mg/kg q3w). Overall, 
while PopPK analysis showed body weight and ALT had 
an influence on PK, their effects were considered to be of 
a nonclinically relevant magnitude. This was confirmed by 
the PK exposure–efficacy–safety analysis showing lack of 
a distinct relationship between Cmin,ss, trastuzumab regi-
men and route of administration, or body weight and pCR 
or AUCss, trastuzumab regimen and route of administration, 
or body weight with grade ≥3 AEs.
In this PopPK analysis, SC and IV trastuzumab serum 

























IV: 8 mg/kg loading, 6 mg/kg maintenance, q3w
IV: 4 mg/kg loading, 2 mg/kg maintenance, qw

























IV: 8 mg/kg loading, 6 mg/kg maintenance, q3w
IV: 4 mg/kg loading, 2 mg/kg maintenance, qw
SC: 600 mg fixed dose, q3w
Fig. 3  Model-predicted concentration–time profiles for the approved 
SC and IV regimens. ALT, alanine transaminase; IV, intravenous; 
q3w, every 3 weeks; SC, subcutaneous. Concentration–time profiles 
are simulated for a 600 mg fixed-dose q3w SC regimen, an 8/6 mg/
kg q3w IV regimen and a 4/2 mg/kg qw IV regimen, using estimated 
population pharmacokinetic parameters for a typical patient (with 
body weight 68 kg and ALT 19 IU/L, as provided in Table 1. Inter-
individual variability and model residual error were not included in 
the simulation). Simulation was performed for seven cycles. Left 
panel shows the profile from cycles 1 to 7; right panel shows cycle 
7 only
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described by a two-compartment model, with first-order 
absorption following SC injection and two parallel linear 
and nonlinear eliminations from the central compartment. 
The nonlinear CL, probably a result of target-mediated 
drug disposition, is consistent with previous reports for 
other monoclonal antibodies [11]. As a result of the nonlin-
ear elimination pathway, trastuzumab elimination is faster 
and the half-life shorter at low compared with high concen-
trations, which is consistent with target-mediated CL that 
gets saturated at higher concentrations. There was a good 
agreement between predicted and observed concentrations, 
and the model mimicked the central tendency and spread of 
the PK of both SC and IV trastuzumab, adequately describ-
ing the distribution of concentrations. At typical steady-
state concentrations, total CL fluctuates due to nonlinearity, 
as trough/peak concentrations fluctuate from 75 to 140 μg/
mL (SC regimen) and 57 to 170 (IV regimen); total CL 
is approximately linear, with the range of 0.22–0.18 and 
0.24–0.17 for the SC and IV regimens, respectively. These 
values are comparable to those seen previously, where tras-
tuzumab PK of weekly IV administration was described 
using a two-compartment model with linear clearance 
(0.225 L/day) [8]. Furthermore, Vc (2.91 L) was consist-
ent with the previous analysis (2.95 L) [8]. Both total CL 
and Vc were also consistent with typical values for other 
humanized IgG1 monoclonal antibodies [5, 22, 23].
Bioavailability of the SC regimen was estimated to be 
77 % (1.45 % RSE), with between-subject variability of 
13.0 and 52.2 % shrinkage. Within-patient PK comparison 
of SC and IV data was not obtained in this study; however, 
the estimated bioavailability was comparable to that seen 
with data from the phase I study (NCT00800436), which 
included four patients who received both SC and IV tras-
tuzumab; SC bioavailability in this study was estimated to 
be 0.873 (6.7 % RSE), with between-subject variability of 
16.9 %, using a population modeling approach [10].
Table 2  Summary of efficacy (pCR) and safety (grade ≥3 AE) by body weight and exposure quartiles
Exposure subgroups are according to predicted values from the final population pharmacokinetic model





Patients in subgroup (n) Responders [n (%)] Patients in subgroup (n) Responders [n (%)]
Baseline body weight quartile (kg)
 <58 62 23 (37) 56 30 (54)
 ≥58, <67 74 32 (43) 63 28 (44)
 ≥67, <79 68 28 (41) 68 31 (46)
 ≥79 59 24 (41) 73 29 (40)
Predicted Cmin,ss quartile (μg/mL)
 <45.9 97 41 (42) 33 12 (36)
 ≥45.9, <61.5 84 36 (43) 45 16 (36)
 ≥61.5, <78.2 57 20 (35) 73 39 (53)
 ≥78.2 22 9 (41) 109 51 (47)
 Missing 3 1 (33) 0 0




Patients in subgroup (n) Patients with AEs [n (%)] Patients in subgroup (n) Patients with AEs [n (%)]
Baseline body weight quartile (kg)
 <59 77 50 (65) 71 37 (52)
 ≥59, <68 84 42 (50) 70 37 (53)
 ≥68, <79 70 31 (44) 71 42 (59)
 ≥79 67 33 (49) 85 43 (51)
Predicted AUCss quartile (μg day/mL)
 <1710 101 55 (54) 47 27 (57)
 ≥1710, <2055 94 51 (54) 52 25 (48)
 ≥2055, <2479 69 31 (45) 81 45 (56)
 ≥2479 31 17 (55) 117 62 (53)
 Missing 3 2 (68) 0 0
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The impact of demographic and pathophysiological 
covariates on the PK of trastuzumab was investigated. 
Baseline body weight and ALT were identified as covari-
ates that had statistically significant effects on trastuzumab 
PK (p < 0.001). Body weight was shown to influence the 
linear CL, Vc, and Vp of trastuzumab, all of which increased 
with increasing body weight. This body weight effect is 
consistent with the previously reported covariate relation-
ships for trastuzumab in patients with MBC [8]. Of note, 
higher ALT (typically linked to slower drug clearance) was 
associated with a higher clearance. The reasons for this 
finding are unknown, and it has also been observed with 
other monoclonal antibodies [6].
Sensitivity analyses assessed the impact of body weight 
and ALT on trastuzumab exposure and showed that while 
body weight had a modest effect on trastuzumab exposure, 
ALT had a minimal effect. In addition, body weight and 
ALT combined explained <10 % of between-subject vari-
ability in linear CL. Although body weight had an impact 
on trastuzumab exposure in the sensitivity analysis, the 
Fig. 4  Odds ratios for a pCR 
subgroups of body weight 
and predicted Cmin,ss quartiles 
(per-protocol population) and 
b rates of grade ≥3 AEs of 
subgroups by body weight 
and predicted AUCss quartiles 
(safety population). AE, adverse 
event; AUCss, steady-state area 
under the curve; Cmin,ss, steady-
state trough concentration; IV, 
intravenous; pCR, pathologic 
complete response;  
SC, subcutaneous
Cmin 46 μg/mL
Body weight 79 kg 
Cmin 62 μg/mL
Cmin 78 μg/mL
Body weight 67 kg 
 Cmin 62 μg/mL
Cmin 46 μg/mL
Cmin 78 μg/mL




Odds ratio (95% CI) (a)
(b)
Favors SCFavors IV
0.0 0.5 1.0 1.5 2.0 2.5 3.0
AUCss 1710 (μg day/mL)
Body weight 79 kg 
AUCss 2055 (μg day/mL)
AUCss 2479 (μg day/mL)
Body weight 68 kg 
AUCss 2055 (μg day/mL)
AUCss 1710 (μg day/mL)
AUCss 2479 (μg day/mL)
Body weight 59 kg
AUCss 2055 (μg day/mL)
AUCss 2479 (μg day/mL)
AUCss 1710 (μg day/mL)
Favors IVFavors SC
0.5 1.0
Odds ratio (95% CI)
1.5 2.0 2.5
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clinical trial simulations confirm previous findings that 
heavier patients who receive the fixed SC dose do not have 
compromised PK exposure compared with patients treated 
with the weight-adjusted IV regimen [10]. While the IV 
regimen overcompensates for body weight, resulting in 
higher Cmin,ss in heavier patients, the reverse is observed 
for the fixed SC regimen (lower Cmin,ss in heavier patients). 
However, the overall distribution of Cmin,ss and AUCss in 
the entire population was similar for both dosing regimens. 
Additionally, the SC regimen achieved similar Cmin,ss com-
pared with the IV regimen in overweight patients, and most 
patients (98 %, 230/234) achieved the target trough concen-
tration of 20 μg/mL (identified as having anti-tumor activ-
ity in preclinical efficacy models [12]) at steady state. Thus, 
neither body weight nor ALT is considered to be clinically 
relevant in the EBC population, as they would not neces-
sitate dose adjustment.
The initial covariate screening based on the PopPK 
model showed that ALBU had a significant effect on CL 
(p = 0.0003). Following the backward elimination step, the 
effect of ALBU was not significant (p > 0.001) although the 
range was narrow (33–60 g/L) (Online Resource 6). ALBU 
level has been inversely associated with the clearance of 
other IgG antibodies [24]; however, in the current analysis, 
despite showing a trend toward an effect, it did not meet the 
predefined statistical criteria for selection as a significant 
covariate. It is hypothesized that ALBU level correlates 
with disease status, whereby patients with more severe dis-
ease have lower ALBU levels and clear IgG more quickly. 
The lack of an ALBU effect in HannaH may be attributed to 
the observed narrow range of relatively normal ALBU lev-
els (33–60 g/L) in the EBC population studied, compared 
with the wider range of those in a more diverse population 
(such as patients with MBC). Renal function (CrCL) had a 
marginal effect on CL (p < 0.01 in the univariate covariate 
screening), but was not a significant covariate in the final 
model (p > 0.001), which may be a consequence of the 
body weight component used in the calculation of CrCL, 
as monoclonal antibodies typically do not have a renal 
clearance component [25, 26]. The development of ADAs 
(including both ATAs and AHAs) did not exhibit statisti-
cally significant effects on trastuzumab PK. However, due 
to the low numbers of ADA-positive patients (5.0 % ATA-
positive and 5.7 % AHA-positive), these results should be 
interpreted with caution.
Conclusion
For patients with HER2-positive EBC, a fixed dose of 
600 mg SC trastuzumab q3w provides the desired PK expo-
sure, with steady-state trough concentrations consistently 
above the historical efficacy target (20 μg/mL), regardless 
of race, body weight, and treatment setting (neoadjuvant or 
adjuvant). Within the ranges studied, the assessed patient 
covariates, including body weight, do not influence trastu-
zumab PK to a magnitude that would require a dose adjust-
ment. The SC dose is further supported by the exposure–
response analyses of pCR and grade ≥3 AEs, which did 
not identify a statistically meaningful impact of either body 
weight, exposure, or route of administration. Similar trastu-
zumab exposure is expected in patients with MBC and sup-
ports the appropriateness of a fixed 600 mg SC dose across 
breast cancer indications.
Acknowledgments The study was funded by F. Hoffmann-La 
Roche Ltd, Basel, Switzerland, and Genentech, Inc., a member of 
the Roche Group, South San Francisco, CA, USA. The authors also 
acknowledge the contributions of the HannaH Study Management 
Team, investigators, research support staff, and clinical pharmacolo-
gists in the design and early conduct of the study, in particular Flor-
ence Hourcade-Potelleret, Christine McIntyre, Michael Brewster, and 
Beate Bittner. The authors would also like to thank all participating 
patients and their families. Support for third-party writing assistance 
for this manuscript was provided by F. Hoffmann-La Roche Ltd.
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://crea-
tivecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
 1. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly 
BM, Fox JA (1999) Nonclinical studies addressing the 
mechanism of action of trastuzumab (Herceptin). Semin Oncol 
26:60–70
 2. Nahta R, Esteva FJ (2006) Herceptin: mechanisms of action and 
resistance. Cancer Lett 232:123–138
 3. Herceptin: Prescribing Information (2014) http://www.gene.
com/download/pdf/herceptin_prescribing.pdf. Accessed 1 Oct 
2014
 4. Herceptin: Summary of Product Characteristics (2011) http://
www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_
Product_Information/human/000278/WC500074922.pdf. 
Accessed 1 Oct 2014
 5. Wynne C, Harvey V, Schwabe C, Waaka D, McIntyre C, 
Bittner B (2013) Comparison of subcutaneous and intravenous 
administration of trastuzumab: a phase I/Ib trial in healthy male 
volunteers and patients with HER2-positive breast cancer. J Clin 
Pharmacol 53:192–201
 6. F. Hoffmann-La Roche Ltd. Data on file
 7. Bittner B, Richter WF, Hourcade-Potelleret F, McIntyre C, 
Herting F, Zepeda ML, Schmidt J (2012) Development of a 
subcutaneous formulation for trastuzumab—nonclinical and 
clinical bridging approach to the approved intravenous dosing 
regimen. Arzneimittelforschung 62:401–409
 8. Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein 
P (2005) Population pharmacokinetics of trastuzumab in patients 
with HER2+ metastatic breast cancer. Cancer Chemother 
Pharmacol 56:361–369
88 Cancer Chemother Pharmacol (2016) 77:77–88
1 3
 9. Charoin JE, Jacqmin P, Banken L, Lennon S, Jorga K (2004) 
Population pharmacokinetic analysis of trastuzumab (Hercep-
tin) following long-term administration using different regimens. 
Population Approach Group in Europe (PAGE) 13: Abstract 489
 10. Hourcade-Potelleret F, Lemenuel-Diot A, McIntyre C, Brewster 
M, Lum B, Bittner B (2014) Use of a population pharmacoki-
netic approach for the clinical development of a fixed-dose sub-
cutaneous formulation of trastuzumab. CPT: Pharmacometrics 
Syst Pharmacol 3:e87
 11. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH (2010) Clini-
cal pharmacokinetics of therapeutic monoclonal antibodies. Clin 
Pharmacokinet 49:493–507
 12. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, 
Coombs D, Baly D, Kabbinavar F, Slamon D (1999) Inhibitory 
effects of combinations of HER-2/neu antibody and chemo-
therapeutic agents used for treatment of human breast cancers. 
Oncogene 18:2241–2251
 13. Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, 
Kim SB, Pienkowski T, Lichinitser M, Semiglazov V, Melichar B, 
Jackisch C (2012) Subcutaneous versus intravenous adminis-
tration of (neo)adjuvant trastuzumab in patients with HER2-
positive, clinical stage I-III breast cancer (HannaH study): a 
phase 3, open-label, multicentre, randomised trial. Lancet Oncol 
13:869–878
 14. Jackisch C, Kim SB, Semiglazov V, Melichar B, Pivot X, 
Hillenbach C, Stroyakovskiy D, Lum BL, Elliott R, Weber HA, 
Ismael G (2015) Subcutaneous versus intravenous formulation of 
trastuzumab for HER2-positive early breast cancer: updated 
results from the phase III HannaH study. Ann Oncol 26:320–325
 15. National Cancer Institute Common Terminology Criteria for 
Adverse Events version 3.0. http://ctep.cancer.gov/protocolD-
evelopment/electronic_applications/docs/ctcaev3.pdf. Accessed 
12 Feb 2015
 16. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, 
Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, 
Slamon DJ (1999) Multinational study of the efficacy and safety 
of humanized anti-HER2 monoclonal antibody in women who 
have HER2-overexpressing metastatic breast cancer that has pro-
gressed after chemotherapy for metastatic disease. J Clin Oncol 
17:2639–2648
 17. FDA, Guidance for Industry: Population Pharmacokinetics 
(1999) http://www.fda.gov/downloads/Drugs/GuidanceCom-
plianceRegulatoryInformation/Guidances/ucm072137.pdf. 
Accessed 1 Oct 2014
 18. R statistical software. http://www.r-project.org/
 19. Mandema JW, Verotta D, Sheiner LB (1992) Building popula-
tion pharmacokinetic–pharmacodynamic models. I. Models for 
covariate effects. J Pharmacokinet Biopharm 20:511–528
 20. Perl speaks NONMEM (PsN 3.4.2). http://psn.sourceforge.net/
download.php#. Accessed 1 Oct 2014
 21. Savic RM, Karlsson MO (2009) Importance of shrinkage in 
empirical Bayes estimates for diagnostics: problems and solu-
tions. AAPS J 11:558–569
 22. Mould DR, Sweeney KRD (2007) The pharmacokinetics and 
pharmacodynamics of monoclonal antibodies—mechanistic 
modeling applied to drug development. Curr Opin Drug Discov 
Dev 10:84–96
 23. Dirks NL, Meibohm B (2010) Population pharmacokinet-
ics of therapeutic monoclonal antibodies. Clin Pharmacokinet 
49:633–659
 24. Fasanmade AA, Adedokun OJ, Olson A, Strauss R, Davis HM 
(2010) Serum albumin concentration: a predictive factor of inf-
liximab pharmacokinetics and clinical response in patients with 
ulcerative colitis. Int J Clin Pharmacol Ther 48:297–308
 25. FDA (1998) Guidance for industry: pharmacokinetics in patients 
with impaired renal function—study design, data analysis, and 
impact on dosing and labeling. http://www.fda.gov/downloads/
Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
ucm072127.pdf. Accessed 1 Oct 2014
 26. Chames P, Van Regenmortel M, Weiss E, Baty D (2009) 
Therapeutic antibodies: successes, limitations and hopes for the 
future. Br J Pharmacol 157:220–233
